AACR IO 2026 Keynote Highlights: Cancer Vaccines Are Here, and Upgrading T Cells To Thrive in the Tumor Microenvironment
Elizabeth M. Jaffee and Philip D. Greenberg opened AACR IO 2026 with a look at cancer vaccines and the...
Elizabeth M. Jaffee and Philip D. Greenberg opened AACR IO 2026 with a look at cancer vaccines and the...
In the first quarter of 2025, the FDA issued 13 approvals for oncology treatments, covering nine types of cancer...
This month, the editors of AACR's journals tout studies showcasing the immunostimulatory impact of senescent cancer cells, a novel...
A promising new personalized vaccine headlines several recent breakthroughs that highlight progress in kidney cancer research.
After Craig Schumpert learned he had lung cancer that had spread to his brain, bones, and lymph nodes, he...
The CheckPoints is a band comprised of cancer researchers, medical oncologists, and other professionals in the field of immuno-oncology.
Multiple myeloma can be tricky to treat, but many treatment options exist, and new research is constantly supporting more.
Natalie Snider-Hoy, a PhD candidate at Wayne State University, attended AACR Early-career Hill Day 2025 to advocate for sustained...
Cancer screenings are key to saving lives. Take colonoscopies, for example, which are estimated to reduce colorectal cancer risk...
The final day of AACR IO highlighted the emerging frontier of glyco-immunology.
The third keynote session at AACR IO highlighted exciting advances in CAR T-cell therapy, including for solid cancers.